Vestal Point Capital LP Takes $31.56 Million Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Vestal Point Capital LP acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 3,350,000 shares of the biopharmaceutical company's stock, valued at approximately $31,557,000. Amicus Therapeutics comprises about 1.9% of Vestal Point Capital LP's holdings, making the stock its 22nd biggest holding. Vestal Point Capital LP owned approximately 1.12% of Amicus Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in FOLD. Virtus Fund Advisers LLC bought a new stake in Amicus Therapeutics in the 4th quarter valued at $29,000. Covestor Ltd increased its holdings in shares of Amicus Therapeutics by 114.9% in the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after purchasing an additional 2,312 shares during the last quarter. R Squared Ltd bought a new position in shares of Amicus Therapeutics in the fourth quarter valued at about $79,000. KBC Group NV raised its position in shares of Amicus Therapeutics by 44.4% in the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock valued at $96,000 after purchasing an additional 3,120 shares during the period. Finally, Sciencast Management LP acquired a new stake in shares of Amicus Therapeutics during the 4th quarter worth about $100,000.

Amicus Therapeutics Price Performance

FOLD traded down $0.08 on Thursday, reaching $6.26. The stock had a trading volume of 2,995,154 shares, compared to its average volume of 2,841,268. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of -34.78, a price-to-earnings-growth ratio of 1.51 and a beta of 0.64. Amicus Therapeutics, Inc. has a fifty-two week low of $5.81 and a fifty-two week high of $12.65. The firm has a 50-day moving average of $7.22 and a 200-day moving average of $8.82.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on FOLD shares. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. The Goldman Sachs Group lowered their target price on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd. Wall Street Zen downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Wells Fargo & Company reduced their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. Finally, UBS Group upped their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Amicus Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $16.22.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.